Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Growth Hormone Deficiency in Children Clinical Trial

Official title:

A Non-interventional, Prospective Study in Germany to Investigate the Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in a Patient Population With Isolated Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03972345
• Other study ID #: GH-4488
• Secondary ID: U1111-1217-5835
• Status: Enrolling by invitation
• Start date: June 21, 2019
• Est. completion date: June 30, 2031

Study information

• Verified date: March 2024
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Participants are free to decide if they want to take part in this study or not. The study will be conducted to collect information about the influence of adherence to growth hormone therapy with Norditropin® in children and teenagers in daily practice in Germany. This study will look mainly at the difference in near final height between children and teenagers who adhere to their therapy plan with Norditropin® to non-adherent patients. Participants will get Norditropin® as prescribed to them by their doctor. The study will last as long as the therapy with growth hormone is seen necessary by the participants' doctors and the participants, up to a maximum of 10 years. During the visits at the participants' doctors participants will be asked to fill in a questionnaire.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 750
• Est. completion date: June 30, 2031
• Est. primary completion date: June 30, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Years to 15 Years

Eligibility

Inclusion Criteria:

• Informed consent of parent or legally acceptable representative of subject and child assent, as age-appropriate must be obtained before any study-related activities.

1. The parent or legally acceptable representative of the child must sign and date the Informed Consent Form (according to local requirements) and

2. The child must sign and date the Child Assent Form or provide oral assent (if required according to local requirements).

• The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.

• Male or female, all age groups equal to or below 15 years with more than 2 years expected remaining treatment time until reaching NFH. Patients who self-inject should be above 8 years of age in order to be able to fill in the questionnaire.

• Children being GH naïve at baseline with one of the following confirmed diagnoses

1. Isolated growth hormone deficiency (iGHD)

2. Small for gestational age (SGA)

Exclusion Criteria:

• Previous participation in this study. Participation is defined as having given informed consent in this study.

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

• Patients who have an expected future duration of therapy of less than 2 years are not eligible for the study.

Related Conditions & MeSH terms

• Born Small for Gestational Age
• Dwarfism, Pituitary
• Endocrine System Diseases
• Growth Hormone Deficiency in Children

Intervention

Drug:
• Norditropin® FlexPro®
Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.

Locations

Country	Name	City	State
Germany	Universitätsklinikum Ulm für Kinder- und Jugendmedizin	Ulm

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Near final height (NFH) standard deviation score (SDS) measured in scores	SDS, -3 to +3	At the end of the study (up to 10 years)
Secondary	Change in growth rate (height velocity standard deviation score, HV SDS)	Score, range -10 to +10	From baseline (month 0) to end of study (up to 10 years)
Secondary	Change in growth rate (HV SDS) between visits (usually patients are seen every 3 to 6 months)	Score, range -10 to +10	From baseline (month 0) to end of study (up to 10 years)
Secondary	Adherence response as indicated in question at the bottom of newly developed Patient Reported Outcome (PRO) questionnaire each time questionnaire is filled out (preferably at each visit)	The following adherence levels will be used: High adherence: above 85.7% of doses administered Medium adherence: 57.1 - 85.7% of doses administered Low adherence: below 57.1% of doses administered	From baseline (month 0) to end of study (up to 10 years)
Secondary	Adherence measured as number of medication devices returned versus number of prescribed devices for the period between visits	Count	From baseline (month 0) to end of study (up to 10 years)
Secondary	Change of self-rated adherence level throughout the study measured in newly developed PRO questionnaire each time questionnaire is filled out (preferably at each visit)	The following adherence levels will be used: High adherence: above 85.7% of doses administered Medium adherence: 57.1 - 85.7% of doses administered Low adherence: below 57.1% of doses administered	From baseline (month 0) to end of study (up to 10 years)